Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Efficacy and Tolerability of IncobotulinumtoxinA for Treating Glabellar Frown Lines in Korean Adults: A Postmarketing Observational Study

Park, Je-Young MD*; Sung, Nak-Kwan PhD; Pitt, Jonathan M. PhD

doi: 10.1097/DSS.0000000000001330
Original Article

BACKGROUND IncobotulinumtoxinA is safe and effective in Caucasian adults. Its effects have been less documented in Asian adults.

OBJECTIVE To describe the efficacy and tolerability of incobotulinumtoxinA for treating glabellar frown lines (GFLs) in South Korean adults.

METHODS South Korean adults aged 18 to 65 years with moderate-to-severe GFLs received a single dose of 10 to 28 U incobotulinumtoxinA during routine clinical practice. After 30 ± 14 days, investigators assessed the efficacy using the Global Aesthetic Improvement Scale and rated tolerability using a 4-point scale.

RESULTS Six hundred seventy-three subjects were enrolled, of which 528 completed the study according to protocol. Glabellar frown lines improved in 98.7% (521/528) of subjects, with 30.8% of cases rated as “very much improved” and 47.4% as “much improved.” The extent of improvement was unaffected by sex, age, and weight but was greater when the time between GFL identification and treatment was <6 months (p < .001) and when concomitant aesthetic nondrug treatments were used (p < .001). For 94% of subjects, tolerability was good or very good. All reported adverse events were transient and mild or moderate in severity.

CONCLUSION IncobotulinumtoxinA was well tolerated and effective for treating moderate-to-severe GFLs in Korean adults irrespective of age, sex, or weight.

*Oracle Dermatology and Plastic Surgery Center, Seoul, Korea;

Sung Nak Kwan Plastic Surgery, Seoul, Korea;

4Clinics, Paris, France

Address correspondence and reprint requests to: Je-Young Park, MD, Oracle Dermatology and Plastic Surgery Center, 4F Miseung Bld, 23 Apgujeong-ro 30-gil, Gangnam-gu, Seoul, 06022, Korea, or e-mail:

Supported by Merz Asia Pacific Pte Ltd.

J.-Y. Park is an advisory board member, speaker, and consultant for Merz Pharmaceuticals, Allergan, and Medytox Inc. J.M. Pitt is an employee of 4Clinics France, who was paid by Merz Pharmaceuticals to prepare this article. The remaining author has indicated no significant interest with commercial supporters.

© 2017 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website